The marketing materials are designed to help people better UNDERSTAND LymPro and where it fits in the AD diagnostic process. This is an important step. Many of us shareholders didn't really understand the difference between univariant and multivariant data when it was presented in July, and some of us have been here for quite some time, myself included!! So now is a good time to start educating people more about LymPro. I am confident that the more people know about LymPro the more attractive it will become compared to it's competition, Amivid.

Mentioning the marketing materials were being printed was the most CONCRETE sign in the blog that the Lympro launch will be starting soon! Generating revenue from LymPro is the catalyst of catalysts, IMHO. Catalysts like a JV partner with up front money, as well as the Diagnostic Division Spin Off are more likely to happen once revenue starts flowing.

We're getting closer.